Biocon Biologics gets full global rights to Adalimumab biosimilar from FKB

Strategic Transactions View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.5%Reaction day

₹399.00

prior close

₹400.60

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.1%+0.4% vs market

Pharmaceuticals peers, median of 155sector+0.0%+0.5% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty Midcap 150 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+0.5

15m

+0.5

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.5+0.1+0.4+0.0+0.5

Next day

-0.2-0.4+0.1-0.2-0.1

-0.9-0.6-0.3-0.9+0.0

-2.0-1.0-1.0-1.5-0.5

-1.9-1.2-0.7-1.6-0.3

-1.4-0.2-1.2-1.0-0.4

-1.4+1.1-2.5+0.4-1.7

15d

-5.0-1.6-3.4-2.4-2.6

-8.0-5.9-2.0-7.9-0.1

-2.8-2.0-0.8-6.4+3.6

-8.0-12.9+4.9-14.4+6.3

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon Biologics, subsidiary of Biocon Ltd, has secured full and exclusive global rights for Hulio (biosimilar Adalimumab) from Fujifilm Kyowa Kirin Biologics (FKB). The new agreement supersedes the existing deal under which Biocon only had commercialization rights. Now Biocon will have end-to-end responsibility for manufacturing and commercialization. Biocon will pay a technology license fee and royalties on sales to FKB, while FKB will offset certain development costs and participate in further development. Commercial production at Biocon facilities will start after technology transfer and regulatory approvals. Adalimumab is one of three immunology biosimilars in Biocon's portfolio.

Likely market impact

Gives Biocon Biologics end-to-end control over Hulio, improving manufacturing flexibility and cost efficiency for this key immunology biosimilar.